



Norliqva[®]
(Amlodipine) Oral Solution

1 mg/mL



Consider this before Crushing/Compounding

Crushed/compounded formulations of tablets are NOT FDA-approved and are NOT tested for safety and efficacy in their manipulated form.

Crushed/compounded formulations have been shown to have a wide variation in potency ranging from 68% to 268% of intended dose.

Norliqva ensures you know what your patient is getting.



1: Gudeman, Jennifer, Michael Jozwiakowski, John Chollet, and Michael Randell. "Potential Risks of Pharmacy Compounding." *Drugs in R&D* 13, no. 1 (2013): 1-8. doi:10.1007/s40268-013-0005-9

Why Norliqva[®]?

- ✓ The first FDA-approved liquid solution of amlodipine for hypertension and coronary artery disease
- ✓ NORLIQVA is indicated for the treatment of hypertension in adults and children 6 years of age and older to lower blood pressure
- ✓ Kid friendly mild peppermint flavor
- ✓ Requires no refrigeration or shaking for convenient use

Amlodipine Comparison Matrix	Norliqva [®]	Crushed/Compounded Amlodipine
FDA-approved ready-made oral solution formulation for adults and children 6 and older	✓	✗
Tested to ensure potency and consistency in dosing	✓	✗
No need to shake, use immediately	✓	✗
Stable 36 month shelf life	✓	✗
Tested to ensure proper dosing for bioequivalence	✓	✗
Kid friendly mild peppermint flavor	✓	✗
Additional preparation required by pharmacist / patient / caregiver	✗	✓

Dosing & Administration

NORLIQVA is an oral solution: 1 mg/mL.

Adult recommended starting dose: 5 mg orally once daily with a maximum of 10 mg orally once daily. Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg orally once daily.

Pediatric starting dose: 2.5 mg to 5 mg orally once daily.

Available At Your Wholesaler: ORDER TODAY

150mL bottle

NDC: 46287-035-15

Important Safety Information

Contraindications

NORLIQVA is contraindicated in patients with sensitivity to amlodipine.

See Next Page for More Important Safety Information

Patients may pay as little as **\$0*** **EasyPay**
COPAY PROGRAM

*Terms, limitations, and restrictions apply
Visit cmppharma.com/easypay for more information

IMPORTANT SAFETY INFORMATION

Indications And Usage

NORLIQVA is a calcium channel blocker for the treatment of:
HYPERTENSION

NORLIQVA is indicated for the treatment of hypertension in adults and children 6 years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

CORONARY ARTERY DISEASE

- Chronic Stable Angina
- Vasospastic Angina (Prinzmetal's or Variant Angina)
- Angiographically Documented Coronary Artery Disease In patients without heart failure or an ejection fraction <40%

Contraindications

NORLIQVA is contraindicated in patients with sensitivity to amlodipine.

Warnings And Precautions

NORLIQVA may cause the following conditions.

- Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis. However, acute hypotension is unlikely.
- Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of NORLIQVA, particularly in patients with severe obstructive coronary artery disease.
- Titrate slowly in patients with severe hepatic impairment.

Most common adverse reactions to amlodipine were edema, dizziness, flushing and palpitation which occurred in a dose related manner. Other adverse reactions not clearly dose-related but reported with an incidence >1.0% are fatigue and nausea.

Talk to your healthcare provider about other possible side effects with NORLIQVA. To report SUSPECTED ADVERSE REACTIONS, contact CMP Pharma, Inc. at 1-844-321-1443 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

Do not exceed doses greater than 20 mg daily of simvastatin.

- CYP3A Inhibitors: Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction.
- CYP3A Inducers: No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers.
- Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily
- Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered.

Dosage And Administration

NORLIQVA is an oral solution: 1 mg/mL. Adult recommended starting dose: 5 mg orally once daily with a maximum of 10 mg orally once daily. Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg orally once daily. Pediatric starting dose: 2.5 mg to 5 mg orally once daily.

Please click link for full Important Safety Information and full Prescribing Information:

<https://www.norliqva.com/prescribing-information>



NOR-00014